What is AltaThera Pharmaceuticals?
AltaThera Pharmaceuticals is a precision medicine enterprise dedicated to enhancing patient outcomes through pioneering scientific advancements. The company's core mission revolves around personalizing cardiovascular drug treatments to address the complexities of diverse patient demographics, particularly in combating the widespread arrhythmia epidemic. Their flagship product, Sotalol IV, is engineered to facilitate a transition from inpatient to outpatient procedures, thereby reducing hospital stays. By leveraging clinical data, AltaThera aims to refine patient care strategies and effectively bridge the divide between cutting-edge scientific discovery and practical clinical application.
How much funding has AltaThera Pharmaceuticals raised?
AltaThera Pharmaceuticals has raised a total of $5.8M across 4 funding rounds:
Multiple Rounds
$2.5M
Private Equity
$3.4M
Unspecified (2015): $500K with participation from Undisclosed
Unspecified (2015): $1M led by Undisclosed
Private Equity (2015): $1M supported by Undisclosed
Private Equity (2016): $3.4M, investors not publicly disclosed
Key Investors in AltaThera Pharmaceuticals
Undisclosed Investors
Undisclosed Investors
What's next for AltaThera Pharmaceuticals?
With the recent influx of major strategic investment, AltaThera Pharmaceuticals is poised for accelerated growth and expansion. This significant backing, part of its $5.9M in total capital raised, signals strong investor confidence in the company's precision medicine approach and its potential to disrupt cardiovascular treatment paradigms. The company is likely to focus on advancing its Sotalol IV product through clinical trials and regulatory pathways, while also exploring further applications of its data-driven platform. This strategic financing will be instrumental in scaling operations, enhancing research and development capabilities, and solidifying its market position in the competitive biopharmaceutical landscape.
See full AltaThera Pharmaceuticals company page
